SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis.

SLFN11介导的核糖体生物合成障碍诱导TP53非依赖性细胞凋亡

阅读:10
作者:Ogawa Akane, Izumikawa Keiichi, Tate Sota, Isoyama Sho, Mori Masaru, Fujiwara Kohei, Watanabe Soyoka, Ohga Takayuki, Jo Ukhyun, Taniyama Daiki, Kitajima Shojiro, Tanaka Soichiro, Onji Hiroshi, Kageyama Shun-Ichiro, Yamamoto Gaku, Saito Hitoshi, Morita Tomoko Yamamori, Okada Masayasu, Natsumeda Manabu, Nagahama Masami, Kobayashi Junya, Ohashi Akihiro, Sasanuma Hiroyuki, Higashiyama Shigeki, Dan Shingo, Pommier Yves, Murai Junko
Impairment of ribosome biogenesis (RiBi) triggered by inhibition of ribosomal RNA (rRNA) synthesis and processing leads to various biological effects. We report that Schlafen 11 (SLFN11) induces TP53-independent apoptosis through RiBi impairment. Upon replication stress, SLFN11 inhibits rRNA synthesis with RNA polymerase I accumulation and increased chromatin accessibility in the ribosomal DNA (rDNA) genes. SLFN11-dependent RiBi impairment preferentially depletes short-lived proteins, particularly MCL1, leading to apoptosis in response to replication stress. SLFN11's Walker B motif (E669), DNA-binding site (K652), dephosphorylation site for single-strand DNA binding (S753), and RNase sites (E209/E214) are all required for the SLFN11-mediated RiBi impairment. Comparable effects were obtained with direct RNA polymerase I inhibitors and other RiBi inhibitory conditions regardless of SLFN11. These findings were extended across 34 diverse human cancer cell lines. Thus, we demonstrate that RiBi impairment is a robust inactivator of MCL1 and an additional proapoptotic mechanism by which SLFN11 sensitizes cancer cells to chemotherapeutic agents.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。